Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir vs valganciclovir prophylaxis for CMV in kidney transplant recipients (China)
ChiCTR2500106690Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of letermovir and valganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Incidence of clinically significant CMV infection. Started Aug 2025; status: recruiting.
02
Drugs
letermovirvalganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ChiCTR2500106690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106690.